Loading...
•
Mar 31, 2023
Axsome Q1 2023 Earnings Report
Axsome reported first quarter results, marked by Auvelity's first full quarter of launch and revenue from Sunosi license agreement.
Key Takeaways
Axsome Therapeutics reported a total revenue of $94.6 million for Q1 2023, driven by net product sales of $28.6 million and license revenue of $65.7 million. Auvelity net product sales were $15.7 million, and Sunosi net product sales were $12.9 million. The company's net loss for the quarter was $11.2 million, or $(0.26) per share.
Total revenue for the first quarter of 2023 was $94.6 million, consisting of net product sales of $28.6 million, license revenue of $65.7 million, and royalty revenue of $0.3 million.
Auvelity net product sales were $15.7 million for the first quarter of 2023.
Sunosi net product sales were $12.9 million for the first quarter of 2023, including $1.7 million in international net sales booked by Axsome.
Net loss for the first quarter of 2023 was $11.2 million or $(0.26) per share.
Revenue by Segment
Forward Guidance
Axsome believes that its current cash, along with the remaining committed capital from the $350 million term loan facility, is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...